Nanotechnology-based strategies as novel therapies in gliomas
Gliomas are the most common malignancies of the brain and have a mean survival of 12 months with only 5-10% of the patients surviving for more than 5 years, independent of treatment after diagnosis. Conventional treatment modalities have found the modest success in reducing tumor burden and metastas...
Saved in:
Published in | Therapeutic delivery Vol. 9; no. 8; pp. 571 - 592 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
England
Future Science Ltd
01.08.2018
Newlands Press 01.08.2018 |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Gliomas are the most common malignancies of the brain and have a mean survival of 12 months with only 5-10% of the patients surviving for more than 5 years, independent of treatment after diagnosis. Conventional treatment modalities have found the modest success in reducing tumor burden and metastases. Presence of different biological barriers and drug-resistance efflux transporters are crucial for tumor recurrence and treatment failure. Nanotechnology may amend these circumstances by targeting residual infiltrating malignant cells with minimal damage to normal cells, on-demand release and an improved cellular uptake by tumor cells. This review highlights the current status and advances in nanotechnology for treatment of gliomas. |
---|---|
ISSN: | 2041-5990 2041-6008 |
DOI: | 10.4155/tde-2018-0022 |